Sopharma AD (SFA) Stock Overview

Produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. More details

SFA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends4/6

SFA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Sopharma AD Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sopharma AD
Historical stock prices
Current Share Priceлв2.60
52 Week Highлв2.70
52 Week Lowлв1.84
Beta-0.20
1 Month Change16.07%
3 Month Change37.32%
1 Year Change32.65%
3 Year Change78.90%
5 Year Change160.00%
Change since IPO26.07%

Recent News & Updates

Sopharma AD's (BUL:SFA) Dividend Will Be BGN0.08

Jul 03
Sopharma AD's (BUL:SFA) Dividend Will Be BGN0.08

Is Sopharma AD (BUL:SFA) A Risky Investment?

Jul 01
Is Sopharma AD (BUL:SFA) A Risky Investment?

Recent updates

Sopharma AD's (BUL:SFA) Dividend Will Be BGN0.08

Jul 03
Sopharma AD's (BUL:SFA) Dividend Will Be BGN0.08

Is Sopharma AD (BUL:SFA) A Risky Investment?

Jul 01
Is Sopharma AD (BUL:SFA) A Risky Investment?

Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit

Sep 07
Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit

Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly

Jun 02
Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly

Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Apr 09
Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching

Feb 20
Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching

How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?

Feb 05
How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?

Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?

Jan 22
Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?

Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

Jan 06
Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years

Dec 22
Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Dec 07
Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?

Nov 19
Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Jul 07
Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Sopharma AD (BUL:3JR) Pays A лв0.07 Dividend In Just 1 Days

Jun 16
Sopharma AD (BUL:3JR) Pays A лв0.07 Dividend In Just 1 Days

Shareholder Returns

SFABG PharmaceuticalsBG Market
7D9.9%-0.5%1.5%
1Y32.7%-21.6%11.8%

Return vs Industry: SFA exceeded the BG Pharmaceuticals industry which returned -21.6% over the past year.

Return vs Market: SFA exceeded the BG Market which returned 11.8% over the past year.

Price Volatility

Is SFA's price volatile compared to industry and market?
SFA volatility
SFA Average Weekly Movement3.8%
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement4.2%
10% most volatile stocks in BG Market6.8%
10% least volatile stocks in BG Market2.6%

Stable Share Price: SFA has not had significant price volatility in the past 3 months compared to the BG market.

Volatility Over Time: SFA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19336,099Ognian Donevwww.sopharmagroup.com

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices, such as gauzes, compresses, and dressing. The company also provides food supplements; medicinal and cosmetic products, including plasters, bandages, herbal cosmetics, and sanitary-hygiene products; concentrates for hemodialysis; and prescription medicines, and OTC and veterinary medical products.

Sopharma AD Fundamentals Summary

How do Sopharma AD's earnings and revenue compare to its market cap?
SFA fundamental statistics
Market capлв1.30b
Earnings (TTM)лв88.47m
Revenue (TTM)лв2.27b
14.7x
P/E Ratio
0.6x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SFA income statement (TTM)
Revenueлв2.27b
Cost of Revenueлв1.77b
Gross Profitлв498.55m
Other Expensesлв410.08m
Earningsлв88.47m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Jul 30, 2025

Earnings per share (EPS)0.18
Gross Margin21.96%
Net Profit Margin3.90%
Debt/Equity Ratio48.5%

How did SFA perform over the long term?

See historical performance and comparison

Dividends

1.9%
Current Dividend Yield
33%
Payout Ratio

Does SFA pay a reliable dividends?

See SFA dividend history and benchmarks
When do you need to buy SFA by to receive an upcoming dividend?
Sopharma AD dividend dates
Ex Dividend DateJul 10 2025
Dividend Pay DateAug 25 2025
Days until Ex dividend3 days
Days until Dividend pay date43 days

Does SFA pay a reliable dividends?

See SFA dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/13 10:23
End of Day Share Price 2025/07/11 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sopharma AD is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mihail DimitrovFirst Financial Brokerage House